<DOC>
	<DOCNO>NCT02070887</DOCNO>
	<brief_summary>The overall aim observational study investigate impact COMT inhibition homocysteine metabolism , vascular physiology correlate neurodegeneration PD patient certain COMT genotype . It design evaluate effect size Hcy lower secondary outcome parameter . Assessment outcome parameter rater-blinded computer-based .</brief_summary>
	<brief_title>Inhibiting COMT Parkinson 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Entacapone</mesh_term>
	<criteria>Age 60 75 year , Caucasian ethnicity , diagnose PD UK brain bank criterion , Hoehn &amp; Yahr scale 2 3 , fertile female use contraception Group 1 : medication Stalevo® ( LDOPA/DDI + Entacapone ) Group 2 : medication Madopar® Sinemet® ( LDOPA/DDI ) methotrexate therapy last 12 month , treatment Tolcapone vitamin B6 , B12 and/or folic acid supplementation last 6 month , pregnancy , intention become pregnant course study , breast feeding , clinically relevant concomitant disease state discretion investigator know suspected noncompliance , drug alcohol abuse , inability follow procedure study , e.g . due language problem , psychological disorder , dementia confusional state subject , participation another study investigational drug within 30 day precede present study , enrolment investigator , his/her family member , employee dependent person .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>